NEW YORK / Nov 08, 2023 / Business Wire / DocGo, a leading provider of technology-enabled mobile health services (Nasdaq: DCGO), today announced that the company will be participating in the following investor conferences during the month of November.
Needham & Company 4th Annual Tech Week
November 15, 2023 – Virtual 1x1 investor meetings, contact your Needham representative for additional information.
Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
November 16, 2023 – 1x1 investor meetings, contact your Canaccord representative for additional information.
BTIG Digital Health Forum
November 20, 2023 – Virtual 1x1 investor meetings, contact your BTIG representative for additional information.
About DocGo
DocGo is leading the proactive health care revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring, and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With mobile health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
| Last Trade: | US$1.03 |
| Daily Change: | -0.01 -0.96 |
| Daily Volume: | 384,544 |
| Market Cap: | US$100.740M |
November 10, 2025 November 04, 2025 October 20, 2025 October 16, 2025 August 07, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load